S. S. Chugh, R. Havmoeller, and K. Narayanan, Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease, Study. Circulation, vol.129, issue.8, pp.837-884, 2010.

L. Heuzey and J. Y. , Épidémiologie, étiologie et mécanisme de la fibrillation atriale

, Académie Nationale de Médecine, 2011.

B. P. Krijthe, A. Kunst, and E. J. Benjamin, Projections on the number of individuals with atrial fibrillation in the European Union, Eur Heart J, vol.34, issue.35, pp.2746-51, 2000.

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial fibrillation as an independant risk factor for stroke : The Framingham study, Stroke, vol.22, issue.8, pp.983-991, 1991.

J. Menke, L. Lüthje, and A. Kastrup, Thromboembolism in atrial fibrillation, Am J Med, vol.105, issue.4, pp.502-512, 2010.

M. Wasilewska and I. Gosk-bierska, Thromboembolism associated with atrial fibrillation as a cause of limb and organ ischemia, Adv Clin Exp Med, vol.22, issue.6, pp.865-73, 2013.

, Haute Autorité de Santé. Les anticoagulants oraux, 2018.

P. Kirchhof, S. Benussi, and D. Kotecha, ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, pp.2893-962, 2016.

G. Y. Lip, R. Nieuxlaat, and R. Pisters, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach, CHEST, vol.137, issue.2, pp.263-72, 2010.

R. Pisters, A. L. Deirdre, and R. Nieuwlaat, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. The Euro Heart Survey, vol.138, pp.1093-100, 2010.

J. J. You, D. E. Singer, and P. A. Howard, Antithrombotic therapy for atrial fibrillation, Chest, vol.141, issue.2, pp.531-575, 2012.

R. G. Hart, O. Benavente, R. Mcbride, and L. A. Pearce, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, vol.131, issue.7, pp.492-501, 1999.

J. Mant, F. D. Hobbs, and K. Fletcher, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet, vol.370, issue.9586, pp.493-503, 2007.

C. B. Granger, J. H. Alexander, and J. H. Mcmurray, Apixaban versus Warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, issue.11, pp.981-92, 2011.

S. J. Conolly, M. D. Ezekowitz, and P. D. , Dabigatran versus Warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, and J. Garg, Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation, N Engl J Med, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

R. P. Giugliano, C. T. Ruff, and E. B. Braunwald, Edoxaban versus Warfarin in patients with atrial fibrillation, N Engl J Med, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

T. F. Chao, C. J. Liu, and Y. J. Lin, Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study, Circulation, vol.138, issue.1, pp.37-47, 2018.

M. Avgil-tsadok, C. Jackevicius, and V. Essebag, Dabigatran use in elderly patients with atrial fibrillation, Thromb Haemost, vol.115, issue.1, pp.152-60, 2016.

C. T. Ruff, R. P. Giugliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, vol.383, issue.9921, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

M. Sharma, V. R. Cornelius, and J. P. Patel, Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism, Circulation, vol.132, issue.3, pp.194-204, 2015.

A. H. Malik, S. Yandrapalli, and W. S. Aronow, Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age, Am J Cardiol, 2019.

S. Fareau, K. Baumstarck, and A. Farcet, Évaluation de la qualité de vie des patients âgés en fibrillation atriale sous anticoagulants au long cours : antivitamine K versus anticoagulants oraux directs. La Revue de Médecine Interne, vol.36, pp.175-181, 2015.

. Hfa-csanz-atrial-fibrillation-guideline-working, . Group, D. Brieger, and A. , National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation, Heart Lung Circ, vol.27, pp.1209-66, 2018.

B. Joung, J. M. Lee, and K. H. Lee, Korean Guideline of Atrial Fibrillation Management, 2018.

, Korean Circ J, 2018.

G. Lip, A. Banerjee, and G. Boriani, Antithrombotic therapy for Atrial Fibrillation, Chest, vol.154, pp.1121-201, 2018.

C. E. Chiang, K. Okumura, and S. Zhang, consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation, Journal of Arrhythmia, vol.33, issue.4, pp.345-67, 2017.

J. G. Andrade, A. Verma, and L. B. Mitchell, focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation, Can J Cardiol, vol.34, pp.1371-92, 2018.

I. M. Ogilvie, N. Newton, and S. A. Welner, Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review, Am J Med, vol.123, issue.7, pp.638-683, 2010.

O. Bahri, F. Roca, and T. Lechani, Underuse of Oral Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in France: Comparisons of Resident Characteristics and Physician Attitude, J Am Geriatr Soc, vol.63, issue.1, pp.71-77, 2015.

Y. Yamashita, Y. Hamatani, and M. Esato, Clinical Characteristics and Outcomes in Extreme Elderly (Age ? 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry, Chest, vol.149, issue.2, pp.401-413, 2016.

D. Mccormick, J. H. Gurwitz, and R. J. Goldberg, Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting, Arch Intern Med, vol.161, issue.20, pp.2458-63, 2001.

D. Gnjidic, S. N. Hilmer, and F. M. Blyth, Polypharmacycutoff and outcomes: five or more medicineswereused to identifycommunity-dwellingolder men at risk of different adverse outcomes, J Clin Epidemiol, vol.65, issue.9, pp.989-95, 2012.

, ANSM. Interactions médicamenteuses et cytochromes, 2017.

J. C. Hsu, T. M. Maddox, and K. F. Kennedy, Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk, JAMA, vol.1, issue.1, pp.55-62, 2016.

G. Maura, C. Billionnet, and J. Drouin, Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, BMJ Open [Internet], vol.9, issue.4, 2011.

A. Helis, Prévalence du traitement anticoagulant dans la prévention embolique de la fibrillation auriculaire chez le patient gériatrique hospitalisé, 2017.

J. Loignon, Evaluation du traitement antithrombotique du sujet de plus de 75 ans aux antécédents de fibrillation auriculaire admis aux urgences du CHRU de Lille

M. Coutauchaud and J. J. , La prescription des anticoagulants en unité de soins longue durée et en soins de suite et de réadaptation du CHU de Bordeaux : Les principaux facteurs associés à l'underuse, 2018.

. Ansm, Les anticogaulants en France en 2014: état des lieux, synthèse et surveillance, 2014.

R. Rahmani, Prescription des anticoagulants en médecine générale, 2014.

A. J. Camm, G. Lip, D. Caterina, and R. , focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, vol.33, issue.21, pp.2719-2766, 2012.

S. B. Freedman, B. J. Gersh, and G. Lip, Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation, Eur Heart J, vol.36, issue.11, pp.653-659, 2015.

S. Henrard, C. Vandenabeele, and S. Marien, Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS2 Score ? 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants? Drugs&Aging, vol.34, pp.841-50, 2017.

A. L. Waldo, R. C. Becker, and V. F. Tapson, Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation, J Am Coll Cardiol, vol.46, issue.9, pp.1729-1765, 2005.

E. R. Mcgrath, A. S. Go, and Y. Chang, Use of oral anticoagulant therapy in older adults with atrial fibrillation after acute ischemic stroke, J Am Geriatr Soc, vol.65, issue.2, 2016.

D. Pugh, J. Pugh, and G. E. Mead, Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review, Age and Ageing, vol.40, issue.6, pp.675-83, 2011.

T. Dreischulte, K. Barnett, and V. Madhok, Use of oral anticoagulants in atrial fibrillation is highly variable and only weakly associated with estimated stroke risk: Cross-sectional population database study, Eur J Gen Pract, vol.20, pp.181-190, 2014.

F. C. Suárez, F. Formiga, and M. Camafort, Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach, BMC Cardiovasc Disord, vol.15, issue.143, 2015.

G. Viscogliosi, E. Ettorre, and I. M. Chiriac, Dementia correlates with anticoagulation underuse in older patients with atrial fibrillation, Arch Gerontol Geriatr, vol.72, pp.108-120, 2017.

J. Donzé, C. Clair, and B. Hug, Risk of falls and major bleeds in patients on oral anticoagulation therapy, Am J Med, vol.125, issue.8, pp.773-781, 2012.

M. Man-son-hing, N. G. Lau, and A. , Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med, vol.159, issue.7, pp.677-85, 1999.

B. F. Gage, E. Birman-deych, and R. Kerzner, Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall, Am J Med, vol.118, issue.6, pp.612-619, 2005.

T. S. Inui, R. Parina, and D. C. Chnag, Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit, J Trauma Acute Care Surg, vol.76, issue.3, pp.642-651, 2014.

A. G. Ording, E. Horváth-puhó, and K. Adelborg, Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study, Cancer Med, vol.6, issue.6, pp.1165-72, 2017.

S. Shah, F. L. Norby, and Y. H. Datta, Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation, Blood adv, vol.2, pp.200-209, 2018.

W. Zhu, R. Wan, and F. Liu, Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review, J Am Heart Assoc, vol.5, issue.9, p.4006, 2016.

F. Andreotti, B. Rocca, and S. Husted, Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis, Eur Heart J, vol.36, issue.46, pp.3238-3287, 2015.

M. Monégat and C. Sermet, La polymédication: définitions, mesures et enjeux. Revue de la littérature et tests de mesure. IRDES, 2014.

B. M. Shah, E. R. Haijar, and . Polypharmacy, Adverse Drug Reactions, and Geriatric Syndromes, Clin Geriatr Med, vol.28, issue.2, pp.173-86, 2012.

G. Kerbiriou, Evaluation du risque hémorragique lié aux anticoagulants oraux: enquête de pratiques auprès des médecins généralistes concernant leurs patients atteints de fibrillation auriculaire, 2017.

M. Gattellari, J. Worthington, and N. Zwar, Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians, Stroke, vol.39, issue.1, pp.227-257, 2007.

M. Man-son-hing and A. Laupacis, Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded, Arch Intern Med, vol.163, issue.13, pp.1580-1586, 2003.

D. Vinereanu, R. D. Lopes, and C. Bahit, A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, clusterrandomised trial, Lancet, vol.390, pp.1737-1783, 2017.

A. Materre, Histoire de l'électrocardiogramme. Limoges, 2016.

H. Sunthorn, J. J. Perrenoud, and D. Shah, Arythmies auriculaires : mécanisme, présentation ECG et traitement curatif. Revue Médicale Suisse, vol.2, 2006.

L. Fauchier, R. Philippart, and N. Clementy, Comment définir la fibrillation atriale valvulaire? Arch Cardiovasc Dis, 2015.

M. A. Mamas, J. C. Caldwell, and S. Chacko, A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure, Eur J Heart Fail, vol.11, issue.7, pp.676-83, 2009.

B. Williams, G. Mancia, and W. Spiering, ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J, vol.00, pp.1-98, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02042368

M. R. Movahed, M. Hashemzadeh, M. Jamal, and M. , Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease, International Journal of Cardiology, vol.105, issue.3, pp.315-323, 2005.

C. Selmer, J. B. Olesen, and M. L. Hansen, The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study, BMJ, 2012.

E. M. Hald, K. F. Enga, and M. L. Lochen, Venous Thromboembolism Increases the Risk of Atrial Fibrillation: The Tromsø Study, J Am Heart Assoc, vol.3, issue.1, p.483, 2014.

S. C. Larsson, N. Drca, and A. Wolk, Alcohol Consumption and Risk of Atrial Fibrillation: A Prospective Study and Dose-Response Meta-Analysis, JACC, vol.64, issue.3, pp.281-290, 2014.

C. S. Van-der-hooft, J. Heeringa, and G. Van-herpen, Drug-induced atrial fibrillation, Journal of the American College of Cardiology, vol.44, issue.11, pp.2117-2141, 2004.

S. S. Chugh, G. A. Roth, R. F. Gillum, and G. A. Mensah, Global burden of atrial fibrillation in developed and developing nations, Global heart, vol.9, issue.1, pp.113-122, 2014.

Y. Miyasaka, M. E. Barnes, and B. J. Gersh, Secular trends in incidence of atrial fibrillation in Olmsted County, Circulation, issue.114, pp.119-144, 1980.

B. P. Krijthe, A. Kunst, and E. J. Benjamin, Projections on the number of individuals with atrial fibrillation in the European Union, Eur Heart J, vol.34, issue.35, pp.2746-51, 2000.

D. Ko, F. Rahman, and R. B. Schnabel, Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis, Nat Rev Cardiol, vol.13, issue.6, pp.321-353, 2016.

P. N. Jensen, E. L. Thacker, and S. Dublin, Racial differences in the incidence of and risk factors for atrial fibrillation in older adults : the cardiovascular health study, J Am Geriatr Soc, vol.61, issue.2, pp.276-80, 2013.

M. H. Kim, S. S. Jonhston, and B. C. Chu, Estimation of total incremental health care costs in patients with atrial fibrillation in the United States, Circulation, vol.4, issue.3, pp.313-333, 2011.

L. Heuzey, J. Y. Paziaud, O. Piot, and O. , Cost of care distribution in atrial fibrillation patients: the COCAF study, American Heart Journal, vol.147, issue.1, pp.121-127, 2004.

, Société Française de Médecine d'Urgence. Prise en charge de la fibrillation auriculaire en médecine d'urgence Recommandations formalisées d'experts, 2015.

S. Faure and J. Buxeraud, Les anticoagulants oraux directs ou AOD. Actualités pharmaceutiques, vol.53, pp.1-10, 2014.

, Agence nationale de sécurité du médicament et des produits de santé. Questions / Réponses pour les professionnels de santé. Quoi de neuf concernant les antivitamines K?, 2018.

C. B. Granger, J. H. Alexander, and J. H. Mcmurray, Apixaban versus Warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, issue.11, pp.981-92, 2011.

S. J. Conolly, M. D. Ezekowitz, and P. D. , Dabigatran versus Warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009.

J. W. Eikelboom, S. J. Connolly, and M. Ezekowitz, Risk of bleeding with 2 doses of Dabigatran compared with Warfarin in older and younger patients with atrial fibrillation An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation, vol.123, issue.21, pp.2363-72, 2011.

H. Autorité-de-santé, Commission de la transparence -dabigatran étexilate, 2016.

M. R. Patel, K. W. Mahaffey, and J. Garg, Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation, N Engl J Med, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

R. P. Giugliano, C. T. Ruff, and E. B. Braunwald, Edoxaban versus Warfarin in patients with atrial fibrillation, N Engl J Med, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

J. W. Eikelboom, D. J. Quinlan, R. Jv, and J. I. Weitz, Idarucizumab : the antidote for reversal of dabigatran, vol.132, pp.2412-2434, 2015.

S. J. Connolly, T. J. Milling, and J. W. Eikelboom, Andexanet Alfa for acute major bleeding associated with factor Xa Inhibitors, vol.375, pp.1131-1172, 2016.

. Le-serment-d'hippocrate, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions

, J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque